Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.74 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.71 |
| ▸ | CHRNG | P07510 | 1/20 | 0.71 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.71 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.71 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.71 |
| ▸ | CHRND | Q07001 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7288917 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL7288922 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL5000883 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL9405507 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL9405545 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL9405509 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL15516162 | 0.89 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7088802 | 0.89 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7669406 | 0.89 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7289188 | 0.88 | SLC6A3 (0.75) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | claimed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | claimed |
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| US-10271540-B2 | Medical fluid, a method of treatment and use of the fluid | XVIVO PERFUSION AB (SE) | 2019-04-30 | — | — | US | disclosed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | disclosed |
| US-20160338343-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20130065218-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | VIVOLINE MEDICAL AB (SE) | 2013-03-14 | — | — | US | disclosed |
| US-20080153870-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2008-06-26 | — | — | US | disclosed |
| US-7291737-B2 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2007-11-06 | — | — | US | disclosed |
| US-7189737-B2 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050197360-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2005-09-08 | — | — | US | disclosed |
| EP-0993301-B1 | COCAINE RECEPTOR BINDING LIGANDS | RES TRIANGLE INST (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6531483-B1 | Treating psychostimulant abuse, inhibiting action of psychostimulant, inhibiting neurotransmitter re-uptake, treating Parkinson's Disease, treating depression | RESEARCH TRIANGLE INSTITUTE | 2003-03-11 | — | — | US | disclosed |
| US-20030023090-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE | 2003-01-30 | — | — | US | disclosed |
| EP-1079833-A4 | COCAINE RECEPTOR BINDING LIGANDS | RES TRIANGLE INST (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6350758-B1 | NOVEL ANALOGS OF COCAINE, ENHANCED ANALGESIC AND/OR VASOCONSTRICTIVE PROPERTIES, INHIBIT THE UPTAKE OF DOPAMINE OR SEROTONIN SO USEFUL FOR TREATING PARKINSON'S DISEASE, DEPRESSION, OR OBESITY, TREATING COCAINE ABUSE, COCAINE | GEORGETOWN UNIVERSITY | 2002-02-26 | — | — | US | disclosed |
| US-6329520-B1 | USED AS IMAGING OR PHARMACEUTICAL AGENTS, IN THE DIAGNOSIS AND TREATMENT OF DRUG ADDICTION, DEPRESSION, ANOREXIA AND NEURODEGENERATIVE DISEASES OR IN DETERMINING DOSES OF THERAPEUTIC AGENTS THAT OCCUPY MANY RECEPTORS | RESEARCH TRIANGLE INSTITUTE | 2001-12-11 | — | — | US | disclosed |
| EP-1079833-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061023-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5935953-A | TROPANE DERIVATIVES AS INHIBITORS TO REDUCE THE FEEDING OF AND DELAYING THE MATURATION OF THE INSECTS AND PESTS; INHIBITORS OF A PHENYLETHANOLAMINE, E.G.OCTOPAMINE, REUPTAKE TRANSPORTER; PESTICIDES; PESTISTATS; INSECTICIDES | RESEARCH TRIANGLE INSTITUTE (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153870-A1 | COCAINE RECEPTOR BINDING LIGANDS | SLC18A2, SLC6A3, SLC18A3 | SLC6A3 2/4885SLC6A2 4/4885SLC6A4 11/4885 |
| US-20030023090-A1 | Cocaine receptor binding ligands | OPRL1, SLC18A2, SLC6A3 | SLC6A3 3/4885SLC6A2 6/4885SLC6A4 5/4885 |
| US-20050197360-A1 | Cocaine receptor binding ligands | SLC18A2, SLC6A3, SLC18A3 | SLC6A3 2/4885SLC6A2 4/4885SLC6A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.